Лучевая диагностика мукормикоза легких

Мукормикоз легких – редко встречающаяся оппортунистическая инфекция, вызванная грибами, которые относятся к порядку Mucorales класса Zygomycetes. Основными факторами риска развития заболевания
являются сахарный диабет и глубокая нейтропения. В последние годы отмечается рост частоты встречаемости мукормикоза, что связывают с более широким применением агрессивных схем химиотерапии, в том числе возрастным пациентам, а также увеличением числа трансплантаций стволовых клеток крови. Заболевание характеризуется тяжелым течением с быстрой генерализацией и высокой летальностью. Применение лучевых методов диагностики – первый способ обследования пациента при подозрении на инфекционный процесс. Выявление характерных признаков мукормикоза позволяет лечащему врачу назначать дальнейшие исследования и поставить ранний диагноз, что в свою очередь значительно улучшает прогноз заболевания.

1. Аравийский Р.А., Климко Н.Н., Васильева Н.В. Диагностика микозов. СПб.: СПбМАПО, 2004. 185 с.

2. Ribes J.A., Vanover-Sams C.L., Baker D.J. Zygomycetes in human disease. Clin. Microbiol. Rev. 2000; 13: 236–301.

3. Хостелиди С.Н. Главное о зигомикозе (обзор). Проблемы медицинской микологии. 2006; 8 (4): 8–18.

4. Thajeb P., Thajeb T., Dai D. Fatal strokes in patients with rhino-orbito-cerebral mucormycosis and associated vasculopathy. Scand. J. Infect. Dis. 2004; 36: 643–648.

5. Goodman & Rinaldi 1991, http://www.rusmedserv.com/mycology/index.html

6. Hibbett D.S., Binder M., Bischoff J.F., Blackwell M., Cannon P.F., Eriksson O.E., Huhndorf S., James T., Kirk P.M., Lücking R., Thorsten Lumbsch H., Lutzoni F., Matheny P.B., McLaughlin D.J., Powell M.J., Redhead S., Schoch C.L., Spatafora J.W., Stalpers J.A., Vilgalys R., Aime M.C., Aptroot A., Bauer R., Begerow D., Benny G.L., Castlebury L.A., Crous P.W., Dai Y.C., Gams W., Geiser D.M., Griffith G.W., Gueidan C., Hawksworth D.L., Hestmark G., Hosaka K., Humber R.A., Hyde K.D., Ironside J.E., Kõljalg U., Kurtzman C.P., Larsson K.H., Lichtwardt R., Longcore J., Miadlikowska J., Miller A., Moncalvo J.M., Mozley-Standridge S., Oberwinkler F., Parmasto E., Reeb V., Rogers J.D., Roux C., Ryvarden L., Sampaio J.P., Schüssler A., Sugiyama J., Thorn R.G., Tibell L., Untereiner W.A., Walker C., Wang Z., Weir A., Weiss M., White M.M., Winka K., Yao Y.J., Zhang N. A higher-level phylogenetic classification of the Fungi. Mycological Res. 2007; 111 (5): 509–547. DOI: 10.1016/j.mycres.2007.03.004.

7. Petrikkos G., Skiada A., Lortholary O., Roilides E., Walsh T.J., Kontoyiannis D.P.. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis. 2012; 54, Suppl 1: S23–S34. DOI: 10.1093/cid/cir866.

8. Bourcier J., Heudes P.M., Morio F., Gastinne T., Chevallier P., Rialland-Battisti F., Garandeau C., Danner-Boucher I., Le Pape P., Frampas E., Moreau P., Defrance C., Peterlin P. Prevalence of the reversed halo sign in neutropenic patients compared with non- neutropenic patients: Data from a single – centre study involving 27 patients with pulmonary mucormycosis (2003–2016). Mycoses. 2017; 60 (8): 526–533. DOI: 10.1111/myc.12624.

9. Spellberg B., Ibrahim A. S. Recent advances in the treatment of mucormycosis. Curr. Infect. Dis. Rep. 2010; 12 (6): 423–429. DOI: 10.1007/s11908-010-0129-9.

10. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., Sein M., Sein T., Chiou C.C., Chu J.H., Kontoyiannis D.P., Walsh T.J. Epidemiology and Outcome of Zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 2005; 41: 634–653. DOI: 10.1086/432579.

11. Климко Н.Н. Микозы: диагностика и лечение. М.: Ви Джи Групп, 2008. 336 с.

12. Lin E., Moua T., Limper A.H. Pulmonary mucormycosis: clinical features and outcomes. Infection. 2017; 45 (4): 443–448. DOI: 10.1007/s15010-017-0991-6.

13. Gleissner B., Schilling A., Anagnostopolous I., Siehl I., Thiel E., Anagnostopolous I., et al. Improved outcome of zygomycosis in patients with hematological diseases? Leukemia Lymphoma. 2004; 45: 1351–1360.

14. Caillot D., Valot S., Lafon I., Basmaciyan L., Chretien M.L., Sautour M., Million L., Legouge C., Payssot A., Dalle F. Is it time to include CT “Reverse Halo Sign” and qPCR targeting mucorales in serum to EORTC-MSG criteria for the diagnosis of pulmonary mucormycosis in leukemia patients? Open forum infectious diseases. Oxford University Press. 2016; 3 (4): fw190. DOI: 10.1093/ofid/ofw190.

15. Millon L., Herbrecht R., Grenouillet F., Morio F., Alanio A., Letscher-Bru V., Cassaing S., Chouaki T., Kauffmann-Lacroix C., Poirier P., Toubas D., Augereau O., Rocchi S., Garcia-Hermoso D., Bretagne S.; French Mycosis Study Group. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin. Microbiol. Infect. 2016; 22: 810. e1–810. e8. DOI: 10.1016/j.cmi.2015.12.006.

16. Millon L., Larosa F., Lepiller Q., Legrand F., Rocchi S., Daguindau E., Scherer E., Bellanger A.P., Leroy J., Grenouillet F. Quantitative polymerase chain reaction detec tion of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin. Infect. Dis. 2013; 56 (10): e95–e101. DOI: 10.1093/cid/cit094.

17. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., Pappas P.G., Maertens J., Lortho lary O., Kauffman C.A., Denning D.W., Patterson T.F., Maschmeyer G., Bille J., Dismukes W.E., Herbrecht R., Hope W.W., Kibbler C.C., Kullberg B.J., Marr K.A., Muñoz P., Odds F.C., Perfect J.R., Restrepo A., Ruhnke M., Segal B.H., Sobel J.D., Sorrell T.C., Viscoli C., Wingard J.R., Zaoutis T., Bennett J.E.; European Organization for Research and Treatment of Cancer/Invasive Fungal-Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin. Infect. Dis. 2008; 46 (12): 1813–1821. DOI: 10.1086/588660.

18. Cornely O.A., Arikan-Akdagli S., Dannaoui E., Groll A.H., Lagrou K., Chakrabarti A., Lanternier F., Pagano L., Skiada A., Akova M., Arendrup M.C., Boekhout T., Chowdhary A., Cuenca-Estrella M., Freiberger T., Guinea J., Guarro J., de Hoog S., Hope W., Johnson E., Kathuria S., Lackner M., Lass-Flörl C., Lortholary O., Meis J.F., Meletiadis J., Muñoz P., Richardson M., Roilides E., Tortorano A.M., Ullmann A.J., van Diepeningen A., Verweij P., Petrikkos G.; European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology. ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis. 2013; Clin. Microbiol. Infect. 2014; 20: 5–26. DOI: 10.1111/1469-0691.12371.

19. Chamilos G., Lewis R.E., Kontoyiannis D.P. Delaying amphotericin B–based frontline therapy significantly increases mortality among patients with gematologic malignancy who have zygomycosis. Clin. Infect. Dis. 2008; 47 (4): 503–509. DOI: 10.1086/590004.

20. Cereser L., Zuiani C., Graziani G., Girometti R., Como G., Zaja F., Bazzocchi M. Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia. La Radiologia Medica. 2010; 115 (2): 205–214. DOI: 10.1007/s11547-009-0433-3.

21. Roy V., Ali L.I., Selby G.B. Routine chest radiography for the evaluation of febrile neutropenic patients after autologous stem cell transplantation. Am. J. Hematol. 2000; 64 (3): 170–174.

22. McAdams H.P., Rosado de Christenson M., Strollo D.C., Patz E.F. Jr. Pulmonary mucormycosis: radiologic findings in 32 cases. Am. J. Roentgenol. 1997; 168 (6): 1541–1548.

23. Hatrick A. G., Matson M. B., Bingham J. B. Invasive pulmonary mucormycosis with vascular involvement. Grand. Rounds. 2001; 2: 8–10. DOI: 10.1102/1470-5206.2001.0013.

24. Hammer M.M., Madan R., Hatabu H. Pulmonary Mucormycosis: Radiologic Features at Presentation and Over Time. Am. J. Roentgenol. 2018; 210 (4): 742–747. DOI: 10.2214/AJR.17.18792.

25. Da Nam B., Kim T.J., Lee K.S., Kim T.S., Han J., Chung M.J. Pulmonary mucormycosis: serial morphologic changes on computed tomography correlate with clinical and pathologic findings. Eur. Radiol. 2018; 28 (2): 788–795. DOI: 10.1007/s00330-017-5007-5.

26. Georgiadou S.P., , Sipsas N.V., Marom E.M., Kontoyiannis D.P. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin. Infect. Dis. 2011; 52 (9): 1144–1155. DOI: 10.1093/cid/cir12.

27. Choo J.Y., Park C.M., Lee H.J., Lee C.H., Goo J.M., Im J.G. Sequential morphological changes in follow-up CT of pulmonary mucormycosis. Diagn. Intervent. Radiol. 2014; 20 (1): 42. DOI: 10.5152/dir.2013.13183.

28. Caillot D., Legouge C., Lafon I., Ferrant E., Pagès P.B., Plocque A., Estivalet L., Valot S., Dalle F., Abou Hanna H., Chretien M.L. Mucormycoses pulmonaires au cours des traitements de leucémies aiguës. Analyse rétrospective d’une série de 25 patients. Revue des Maladies Respiratoires. 2018. DOI: 10.1016/j.rmr.2017.11.009.

29. Voloudaki A.E., Bouros D.E., Froudarakis M.E., Datseris G.E., Apostolaki E.G., Gourtsoyiannis N.C. Crescentic and ring- shaped opacities. CT features in two cases of bronchiolitis obliterans organizing pneumonia (BOOP). Acta Radiol. 1996; 37: 889–892.

30. Godoy M.C.B., Viswanathan C., Marchiori E., Truong M.T., Benveniste M.F., Rossi S., Marom E.M. The reversed halo sign: update and differential diagnosis. Br. J. Radiol. 2012; 85: 1226–1235. DOI: 10.1259/bjr/54532316.

31. Rea G., Dalpiaz G., Vatrella A., Damiani S., Marchiori E. The reversed halo sign: also think about chronic eosinophilic pneumonia. J. Brasileiro de Pneumologia. 2017; 43 (4): 322–323. DOI: 10.1590/S1806-7562017000000077.

32. Marchiori E., Marom E.M., Zanetti G., Hochhegger B., Irion K.L., Godoy M.C.B. Reversed halo sign in invasive fungal infections: criteria for differentiation from organizing pneumonia. Chest J. 2012; 142: 1469. DOI: 10.1378/chest.12-0114.

33. Marchiori E., Hochhegger B., Zanetti G. Reversed halo sign in invasive fungal infections. Jornal Brasileiro de Pneumologia. 2016; 42 (3): 232–232. DOI: 10.1590/S1806-37562016000000119.

34. Marchiori E., Menna Barreto M., Pereira Freitas H.M., Hochhegger B., Soares Souza A Jr., Zanetti G., Dias Mançano A., Souza Rodrigues R. Morphological characteristics of the reversed halo sign that may strongly suggest pulmonary infarction. Clin. Radiol. 2018; 73 (5): 503. e7–503. e13. DOI: 10.1016/j.crad.2017.11.022.

35. Wahba H., Truong M.T., Lei X., Kontoyiannis D.P., Marom E.M. Reversed halo sign in invasive pulmonary fungal infections. Clin. Infect. Dis. 2008; 46: 1733–1737. DOI: 10.1086/587991.v.

36. Jung J., Kim M.Y., Lee H.J., Park Y.S., Lee S.O., Choi S.H., Kim Y.S., Woo J.H., Kim S.H. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin. Microbiol. Infect. 2015; 21 (7): 684. e11–684. e18. DOI: 10.1016/j.cmi.2015.03.019.

37. Legouge C., Caillot D., Chrétien M.L., Lafon I., Ferrant E., Audia S., Pagès P.B., Roques M., Estivalet L., Martin L., Maitre T., Bastie J.N., Dalle F. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin. Infect. Dis. 2013; 58 (5): 672–678. DOI: 10.1093/cid/cit929.